Responses
Regular and Young Investigator Award Abstracts
Combination Immunotherapies
849 NT-I7, a novel long-acting interleukin-7, improves engraftment of patient immune cells and efficacy of anti-PD-1 therapy in a preclinical humanized melanoma model
Compose a Response to This Article
Other responses
No responses have been published for this article.